Engineering of a human kringle domain into agonistic and antagonistic binding proteins functioning in vitro and in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 21, 2010, Pages 9567-9571

  Lee, Chang Han ^a   Park, Kyung Jin ^a   Sung, Eun Sil ^a   Kim, Aeyung ^a   Choi, Ji Da ^b   Kim, Jeong Sun ^c   Kim, Soo Hyun ^b   Kwon, Myung Hee ^d   Kim, Yong Sung ^a  

^a Ajou University   (South Korea)

^b Konkuk University   (South Korea)

^c Chonnam National University   (South Korea)

^d Ajou University School of Medicine   (South Korea)

Author keywords

Alternative protein scaffold; Nonantibody scaffold; Protein engineering

Indexed keywords

BINDING PROTEIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; KRINGLE DOMAIN; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN FOLDING;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; FEMALE; HUMANS; KRINGLES; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN ENGINEERING; PROTEIN FOLDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STRUCTURE, TERTIARY; PROTEINS; SACCHAROMYCES CEREVISIAE; SEQUENCE ALIGNMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EUKARYOTA;

EID: 77953089168     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1001541107     Document Type: Article

References (27)

1. Lerner RA (2006) Manufacturing immunity to disease in a test tube: The magic bullet realized. Angew Chem Int Ed Engl 45:8106-8125.
2. Skerra A (2007) Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 18:295-304.
3. Binz HK, Amstutz P, Pluckthun A (2005) Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 23:1257-1268.
4. Binz HK, et al. (2004) High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 22:575-582.
5. Schneider S, et al. (1999) Mutagenesis and selection of PDZ domains that bind new protein targets. Nat Biotechnol 17:170-175.
6. Malabarba MG, et al. (2001) A repertoire library that allows the selection of synthetic SH2s with altered binding specificities. Oncogene 20:5186-5194.
7. Nord K, et al. (1997) Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol 15:772-777. (Pubitemid 27329481)
8. Beste G, Schmidt FS, Stibora T, Skerra A (1999) Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc Natl Acad Sci USA 96:1898-1903.
9. Silverman J, et al. (2005) Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains. Nat Biotechnol 23:1556-1561.
10. Schonfeld D, et al. (2009) An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc Natl Acad Sci USA 106:8198-8203.
11. Letunic I, et al. (2006) SMART 5: Domains in the context of genomes and networks. Nucleic Acids Res 34:D257-260.
12. Cao Y, Cao R, Veitonmaki N (2002) Kringle structures and antiangiogenesis. Curr Med Chem Anticancer Agents 2:667-681.
13. Castellino FJ, Beals JM (1987) The genetic relationships between the kringle domains of human plasminogen, prothrombin, tissue plasminogen activator, urokinase, and coagulation factor XII. J Mol Evol 26:358-369.
14. O'Reilly MS, et al. (1997) Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285.
15. Rios-Steiner JL, Schenone M, Mochalkin I, Tulinsky A, Castellino FJ (2001) Structure and binding determinants of the recombinant kringle-2 domain of human plasminogen to an internal peptide from a group A Streptococcal surface protein. J Mol Biol 308:705-719.
16. Marti DN, Schaller J, Llinas M (1999) Solution structure and dynamics of the plasminogen kringle 2-AMCHA complex: 3(1)-helix in homologous domains. Biochemistry 38:15741-15755.
17. Ashkenazi A, et al. (1999) Safety and antitumor activity of recombinant soluble Apo2 ligand. J Clin Invest 104:155-162.
18. Ashkenazi A, Herbst RS (2008) To kill a tumor cell: The potential of proapoptotic receptor agonists. J Clin Invest 118:1979-1990.
19. Sung ES, et al. (2009) A novel agonistic antibody to human death receptor 4 induces apoptotic cell death in various tumor cells without cytotoxicity in hepatocytes. Mol Cancer Ther 8:2276-2285.
20. Kim MS, et al. (2007) Comparative analyses of complex formation and binding sites between human tumor necrosis factor-alpha and its three antagonists elucidate their different neutralizing mechanisms. J Mol Biol 374:1374-1388.
21. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP (2008) Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol Ther 117:244-279.
22. Park KJ, et al. (2007) A human scFv antibody against TRAIL receptor 2 induces autophagic cell death in both TRAIL-sensitive and TRAIL-resistant cancer cells. Cancer Res 67:7327-7334.
23. Song MY, et al. (2008) Characterization of a novel anti-human TNF-alpha murine monoclonal antibody with high binding affinity and neutralizing activity. Exp Mol Med 40:35-42.
24. Angermuller S, Kunstle G, Tiegs G (1998) Pre-apoptotic alterations in hepatocytes of TNFalpha-treatedgalactosamine-sensitized mice. JHistochemCytochem46:1175-1183. (Pubitemid 28445291)
25. Lee HW, et al. (2006) Construction and characterization of a pseudo-immune human antibody library using yeast surface display. Biochem Biophys Res Commun 346:896-903.
26. Kolmar H (2008) Alternative binding proteins: Biological activity and therapeutic potential of cystine-knot miniproteins. Febs J 275:2684-2690.
27. Collis AV, Brouwer AP, Martin AC (2003) Analysis of the antigen combining site: Correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J Mol Biol 325:337-354.